Author: toxlaw

A declining percentage can coexist with a growing death toll. In a historical Los Angeles County study, cardiovascular involvement accounted for a smaller share of methamphetamine-related deaths as opioid co-involvement increased. Reading that pattern as evidence that methamphetamine had become less harmful to the heart would go beyond what the records establish.

Which deaths entered the study?

Shover and colleagues analyzed 6,125 medical-examiner cases from January 1, 2012, through June 30, 2021. Methamphetamine had to be listed in a cause-of-death, contributing-factor or injury-description field. A positive toxicology finding alone, without a listing in those fields, did not qualify a case for inclusion.

This was a retrospective observational analysis of recorded death determinations. It was not an experiment exposing people to drugs, and it was not a study of every person with detectable methamphetamine. The case definition selected deaths in which investigators had already attributed some relevance to methamphetamine.

How did the total and the composition change?

The annual number increased from 238 in 2012 to 1,385 in 2020, the last complete calendar year available. The 2021 data contained 671 cases through June 30. That half-year count should not be labeled a full-year total or mechanically compared with a complete year as though the observation periods were equal.

Selected counts in the published table; the final column covers only January–June 2021.

Recorded feature	2012: 238 deaths	January–June 2021: 671 deaths
Cardiovascular involvement	113, approximately 47%	172, approximately 26%
Opioid involvement	37, approximately 16%	363, approximately 54%
Fentanyl involvement	0	311, approximately 46%

These categories were not mutually exclusive. A death could involve cardiovascular disease, methamphetamine and an opioid. Adding their percentages would therefore misrepresent the classification. The full study period included 2,331 deaths with cardiovascular involvement, or approximately 38% of the 6,125 cases.

Why does the denominator change the interpretation?

The cardiovascular percentage used methamphetamine-related deaths in that period as its denominator. It did not use all people taking methamphetamine, the number of exposure episodes, or person-years of follow-up. If deaths involving another mechanism expand rapidly, the cardiovascular fraction can fall without demonstrating a lower cardiovascular risk among exposed people.

The count comparison itself also resists a reassuring interpretation: 172 cardiovascular-involved deaths appeared in the partial final year, versus 113 in the complete first year. This observation is not an annualized rate calculation. It simply illustrates why a smaller fraction cannot be substituted for a smaller number or a lower exposure-specific risk.

Does opioid co-involvement prove that methamphetamine was contaminated?

No. The records showed an increasing contribution of opioids, particularly fentanyl, to these deaths. They did not establish whether each person knowingly used separate drugs, knowingly used a combined product, or unknowingly encountered an opioid. The authors explicitly acknowledged that co-occurrence could not distinguish intentional from unintentional co-use.

A death record is not a chemical analysis of the product consumed, a reconstruction of ingestion order, or a direct measurement of intent. The population pattern can motivate further investigation of changing supply and use practices. It cannot determine an individual product’s composition or a decedent’s knowledge.

Could examination practices affect the organ-system trend?

Yes. The authors noted that full autopsies had generally been performed in suspected overdoses before 2020, with rare exceptions. During the increased pandemic caseload, detailed postmortem examinations may have been less frequent in some cases with other evidence pointing to a drug-related death.

Conditions requiring internal examination could consequently have been under-recorded. That is a measurement limitation, not proof that the entire cardiovascular trend was an artifact. It nevertheless prevents treating changes in the recorded organ-system distribution as a direct readout of changing biological toxicity.

What other uncertainty remains?

The classification depended on death-certificate descriptions and the medical examiner’s determinations. Manual coding had high agreement in a sampled double-coding exercise, but agreement between coders does not independently validate every underlying cause-of-death attribution. Recorded housing status was also partly subjective, and its misclassification could operate in either direction.

The study described one jurisdiction and a defined historical period. Its proportions should not be presented as current national figures. It also did not estimate survival probabilities or individual drug-concentration thresholds.

What is the useful conclusion for a case review?

Request the actual case definition, calendar window and denominator behind a reported trend. Separate methamphetamine detection from attributed involvement, distinguish overlapping causes, and account for changes in examination practices. This study establishes a major shift in the composition of recorded Los Angeles deaths. It does not establish a protective change in cardiovascular effects or explain the mechanism and intent in every individual death.

Scientific source

Shover CL, Friedman JR, Romero R, et al. Longitudinal changes in co-involved drugs, comorbidities, and demographics of methamphetamine-related deaths in Los Angeles County. Journal of Substance Use and Addiction Treatment. 2023;151:209101. doi:10.1016/j.josat.2023.209101. Historical observational medical-examiner record study.

A lower brain-imaging measurement is a finding to interpret, not a direct count of dead neurons. In a historical 1998 study, McCann and colleagues found reduced dopamine transporter binding in small groups with histories of methamphetamine or methcathinone use. The authors considered neurotoxicity a possible explanation while explicitly retaining neuroadaptation as an alternative.

Who was actually studied?

The observational human study included ten controls, six people with a history of methamphetamine use, four with a history of methcathinone use, and three patients with newly diagnosed Parkinson disease. Methcathinone is a separate drug; its four participants should not be added to the methamphetamine group and described as ten methamphetamine participants.

The methamphetamine participants were recruited from rehabilitation groups. Methcathinone participants were identified through drug-enforcement contacts while incarcerated. Both groups reported other recreational drug use as well. Exposure histories came from interviews and questionnaires, including reported amounts, routes and periods of use; investigators did not administer a standardized methamphetamine regimen or retrospectively verify its purity.

Participants reported approximately three years of abstinence on average, with considerable individual variation. Serum and urine immunoassay screens were negative for recent drug use before imaging. Those screens supported the absence of recently detectable exposure under the testing conditions. They could not independently verify every month of the retrospectively reported abstinence period.

What did the PET scan measure?

Investigators administered the radiotracer [¹¹C]WIN-35,428 intravenously and measured its regional behavior over a 90-minute scanning period. The tracer binds dopamine transporters. A compartment model produced binding potential, expressed as the ratio k3/k4, for the caudate nucleus and putamen.

Binding potential is a modeled tracer measurement. It is not a methamphetamine concentration in whole blood, a dopamine concentration, or a histological neuron count. The paper itself notes that binding can reflect properties of transporter availability and ligand binding. A percentage difference in binding cannot simply be renamed the percentage of neurons lost.

How large were the reported differences?

Table 3 gives uncorrected mean binding potentials of 7.5 in the caudate and 7.3 in the putamen for controls, compared with 5.8 and 5.5, respectively, in the six methamphetamine participants. These correspond to the approximately 23% and 25% reductions described in the paper. They are group comparisons, with variation within groups, rather than individual diagnostic thresholds.

Age required attention. The mean ages were 30.5 years for controls, 37.5 for the methamphetamine group and 53.3 for the Parkinson group. The authors analyzed age as a covariate and also applied a separate age-correction procedure. The methamphetamine comparisons remained significant under both approaches. One methcathinone putamen comparison ceased to be significant after the separate correction, an important qualification to any combined “amphetamine users” summary.

Why was Parkinson disease included?

The three Parkinson patients provided a clinical comparison with a condition involving dopaminergic degeneration. They had substantially lower putamen binding than the other groups. The methamphetamine and methcathinone participants did not show clinical parkinsonism on the neurological assessment.

A shared direction of change in an imaging marker does not establish that two groups have the same disease. Nor did the absence of a significant caudate difference between the small Parkinson and drug-history groups establish equivalence. With only three Parkinson patients and six methamphetamine participants, uncertainty is substantial.

Did the study distinguish injury from adaptation?

Not conclusively. The authors favored a possible neurotoxic contribution based partly on prior animal work, but acknowledged that persistent transporter reduction could reflect neuroadaptation without actual terminal degeneration. This human study did not include brain histology or a pre-exposure scan of the same participants.

Selection into the groups, co-use of other drugs, retrospective exposure reports and unmeasured pre-existing differences also limit causal interpretation. A cross-sectional scan after a reported abstinence period can show an association at that examination. It does not demonstrate the participant’s trajectory from a known personal baseline or establish that the observed difference is irreversible.

Can it predict future disease or current impairment?

The authors raised future parkinsonism as a question requiring longitudinal research. The study did not follow these groups to measure an incidence rate or calculate an individual’s future probability of Parkinson disease. That proposed concern must remain distinct from an observed outcome.

Likewise, the PET findings do not establish an individual’s driving impairment, cognitive capacity or cause of a current complaint. A client explanation should preserve the drug-specific groups, the imaging endpoint and the historical uncertainty: lower transporter binding was observed; neuronal death, permanent functional loss and future disease were not directly established by this experiment.

Scientific source

McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [¹¹C]WIN-35,428. Journal of Neuroscience. 1998;18(20):8417–8422. doi:10.1523/JNEUROSCI.18-20-08417.1998. Historical observational human study.

“Young animals were less sensitive” is incomplete unless the endpoint and time of measurement are specified. A rodent can show a smaller acute biochemical change while still developing later behavioral differences. Phillips and Aldrich’s review of peri-adolescent methamphetamine and amphetamine exposure illustrates why immediate toxicity, subsequent learning and motivation cannot be collapsed into a single vulnerability ranking.

What kind of source is this?

The historical narrative review appeared online in 2021 and in International Review of Neurobiology, volume 161, in 2022. It examined existing animal studies rather than enrolling human adolescents or conducting a new experiment. The authors did not claim to summarize every relevant publication.

In the rodent framework described by the review, peri-adolescence was approximately postnatal days 28–42, although individual experiments used different age boundaries. Those numbers describe days after birth in the animals studied. They do not establish an exact conversion to human chronological age, and a study spanning a different developmental window should retain its actual exposure ages.

What did “less acute toxicity” refer to?

Several comparisons found less depletion of dopamine-system markers in peri-adolescent than adult rodents following binge-like methamphetamine administration. Those endpoints included dopamine content and proteins involved in dopamine function. A smaller change in a selected marker does not establish that every relevant brain process was unaffected.

The review also explains that baseline marker levels, drug exposure and temperature can complicate age comparisons. In some work, older animals had greater baseline levels of the measured marker. A larger absolute reduction can therefore reflect both the exposure response and the starting measurement. In another comparison, adults had higher plasma and striatal methamphetamine concentrations after the nominal dosing regimen. Equal administered doses need not establish equal measured internal exposure.

Why does the temperature example matter?

One experiment summarized in the review used male Sprague–Dawley rats at postnatal day 20, 40 or 60. Methamphetamine was given subcutaneously at 10 mg/kg per injection, four injections separated by two hours. All ages were examined at an ambient temperature of 22°C; the day-20 and day-40 groups were also examined at 30°C.

At 22°C, the review reports reduced neostriatal dopamine and increased glial fibrillary acidic protein in the adult group. At 30°C, those changes were also observed in the day-40 group, but not the day-20 group. This is a description of the Cappon experiment as reported in the review, not an independently reviewed primary-source analysis.

The relevant lesson is conditionality: the apparent age pattern depended partly on the experimental environment and endpoint. These high-dose injected animal conditions do not define a safe temperature, dose or exposure pattern for people.

Why are long-term outcomes a separate question?

The review describes lasting differences in some learning, reward and social measures after early exposure, including studies without apparent acute neurotoxicity on the markers selected. Other outcomes were null, and findings varied by species, strain, sex, regimen and age at testing. Behavioral stimulation, conditioned reward and drug self-administration also measure different constructs; the amount an animal moves is not a universal measure of addiction risk.

Timing introduces another distinction. A group exposed early and tested in adulthood differs from an adult-exposed group tested immediately afterward in both developmental stage and time since exposure. Matching the age at testing makes the abstinence intervals different; matching the interval can make the testing ages different. A credible developmental interpretation must explain how the experiment handled those alternatives.

What comparison is needed to claim a uniquely adolescent effect?

Drug-exposed peri-adolescent animals compared with same-age saline controls can demonstrate an exposure-related difference within that age group. They cannot, by themselves, establish that the effect is larger, smaller or unique compared with adult-initiated exposure. The review repeatedly identifies the missing adult-exposure comparison as a limitation.

A stronger design includes both exposure ages, appropriate controls, clearly defined testing intervals and comparable administration conditions. Even then, a finding concerns the model and outcome tested. It is not an individualized prediction that a particular human adolescent will develop dependence, permanent injury or a specific cognitive deficit.

How should this evidence be used in a client explanation?

Keep three questions separate: what changed soon after exposure, what persisted later, and whether age at exposure modified that change. Preserve the administered drug, route, units, developmental window and testing interval. Describe evidence of reduced acute sensitivity alongside longer-term adverse and null findings.

The review supports careful investigation of developmental effects. It does not support reassuring a client that younger age protects against methamphetamine harm, or inferring an individual’s present impairment from a history of adolescent use.

Scientific source

Phillips TJ, Aldrich SJ. Peri-adolescent exposure to (meth)amphetamine in animal models. International Review of Neurobiology. 2022;161:1–51. Published online August 20, 2021. doi:10.1016/bs.irn.2021.06.011. Original commentary on the supplied historical review; underlying experiments are discussed through that source.

A review containing more methamphetamine-related deficits than amphetamine-related deficits does not necessarily show that methamphetamine produces a larger effect under equivalent conditions. The comparison depends on which animals, exposure schedules and tests entered the evidence base. A 2026 systematic review makes that problem particularly visible: its 37 included publications were divided into 27 methamphetamine studies and 10 amphetamine studies, with substantial differences in experimental methods.

What evidence did the review actually collect?

Poorvii and colleagues searched four databases on December 1, 2025, and included original English-language rodent studies published between 1971 and 2025. The review required an abstinence period and relevant behavioral testing. It was a synthesis of animal experiments, not a new human withdrawal trial, a clinical prognosis study or a pooled estimate of individual impairment.

The number 37 counts publications. It does not count independent people, and it should not be quoted as though 37 experiments all used the same protocol. The article organized findings by tasks such as object recognition, object placement, water mazes, temporal-order memory and attentional learning. These tasks operationalize different abilities; a deficit on one cannot silently become a deficit on all of them.

Why is an apparent drug difference difficult to interpret?

Methamphetamine studies commonly used intraperitoneal administration, but the collection also included intravenous self-administration, subcutaneous injection and oral exposure. Amphetamine protocols likewise varied in route, repetition and escalation. An injected dose expressed in mg/kg, an infusion dose, and a drug concentration in drinking water are different exposure descriptions.

The reviewers considered methamphetamine findings more consistent, while acknowledging broader dosing ranges, higher maximum doses and greater use of extended-access procedures in that literature. Those differences provide competing explanations for the pattern. A fair drug comparison would need appropriately matched exposure conditions, animal characteristics, withdrawal intervals and outcomes. Counting positive findings across unequal literatures does not supply that comparison.

Which null findings should remain visible?

The review’s own tables contain important exceptions. Table 5 describes the North study as finding impaired spatial recognition at 7, 14 and 21 days after methamphetamine exposure, while object recognition was unaffected. Table 6 describes an amphetamine study by Russig and colleagues as showing no impairment of spatial acquisition or retention, together with enhanced reversal learning. These are findings reported through the review; they are not presented here as independently reanalyzed primary experiments.

The distinctions matter. Remembering where an object was located differs from recognizing the object. Learning an initial platform location differs from changing to a new one. A result can therefore be positive for one endpoint and null or improved for another without inconsistency. An absence of statistical significance also does not establish exact equivalence.

How strong was the review’s assessment of bias?

The authors used the SYRCLE animal-study risk-of-bias framework. Many ratings were unclear because allocation concealment, blinding and housing procedures were insufficiently reported. An unclear rating does not prove that investigators used a poor method; it means the published information does not let a reader establish the safeguard.

A separate limitation deserves particular attention: the review states that only statistically significant results were discussed, despite its tables retaining a number of null findings. Emphasizing significance can make a heterogeneous literature sound more uniformly adverse than the complete endpoint record supports. The reader should examine the tables alongside the narrative and resist converting the discussion into a prevalence estimate for cognitive injury.

Can these findings establish a human recovery timetable?

No. Animals were tested after specified withdrawal intervals, but those intervals cannot be converted directly into a person’s number of days to recovery. Routes, cumulative intake, species, strain, sex and task demands all influence the comparison. A controlled animal experiment may support an exposure effect within its own model while remaining insufficient to explain a particular person’s symptoms.

For a case assessment, the useful contribution is methodological: identify the exact claimed ability, distinguish active exposure from withdrawal, preserve null outcomes, and ask whether the cited regimen actually resembles the question being addressed. Neither a positive methamphetamine test nor this review alone establishes current impairment or the cause of an individual’s cognitive difficulty.

Scientific source

Poorvii R, Mohamed IN, Yahaya MF, et al. Cognitive effects of methamphetamine and amphetamine withdrawal in rodents: a systematic review. Frontiers in Psychology. 2026;17:1729722. doi:10.3389/fpsyg.2026.1729722. Original commentary on the supplied review; the historical experiments discussed above are identified through that review.

A postmortem GHB result slightly above an interpretive cutoff does not become certain evidence of ingestion because it is printed to two decimal places. The laboratory needs a method suitable for that matrix and concentration, and the biological interpretation needs the specimen history. Numerical resolution, analytical uncertainty and uncertainty about the source of GHB are different issues.

What kind of source raised this concern?

Pirani and Busardò addressed these issues in a methodological letter published online in 2020. It was commentary on another publication, not a new autopsy series, dosing experiment or independent validation. It therefore supplies a reasoned critique and questions to investigate; it does not provide a new sample size or experimentally established error rate.

The letter supported using multiple matrices while emphasizing missing information about storage, decomposition, analytical validation and the brain region sampled. Its central practical point was that adding specimens does not compensate for an inadequately characterized measurement process.

A cutoff, a quantification limit and uncertainty answer different questions

An interpretive cutoff is a proposed decision threshold used to assess the possible origin of GHB. A quantification limit concerns the concentration at which a method can produce quantitatively acceptable results. Neither is itself a measurement-uncertainty interval.

The letter recommended sensitive, properly validated methods with a quantification limit below the proposed cutoff. A method that only begins quantifying at the decision point provides little information about results immediately below it. Reporting a precise-looking number does not resolve that limitation.

Likewise, a printed value only slightly above a threshold does not show whether a repeat measurement or an uncertainty assessment would remain above it. That question requires the laboratory’s actual performance data and decision approach. An uncertainty interval cannot be invented from the number of decimal places.

What useful validation evidence looks like

A separate primary study by Andresen-Streichert and colleagues illustrates the kinds of details that can be reported. Their derivatization GC–MS method had a detection limit of 0.5 mg/L, quantification limit of 0.6 mg/L and linear calibration range of 1–100 mg/L. They reported accuracy of at least 91% and imprecision of 9% or less at tested controls.

Those are validation results, not a ready-made uncertainty interval for another laboratory’s case result. They also do not validate every possible postmortem matrix or concentration. The study used different control matrices for blood, urine and the other fluids and examined whether aqueous calibration produced comparable results to serum or saline calibration.

That distinction matters when reviewing the letter’s concern about non-matrix-matched calibration. The concrete question is whether a laboratory has demonstrated suitable performance in the relevant matrix. The mere word “water” on a calibrator preparation sheet does not quantify a case-specific error.

Analytical confidence does not settle biological origin

Even a well-supported quantitative result cannot, by analytical precision alone, distinguish ingested GHB from GHB formed after death or during storage. The letter emphasized refrigeration history, decomposition and specimen selection for this reason. Those uncertainties require biological and case evidence beyond the instrument output.

For brain specimens, the sampled region should be identified. For blood, the collection site should be identified. The interval before collection and subsequent storage time and temperature should remain separate. A universal uncertainty percentage cannot account for all those processes.

What to request for a near-threshold result

Useful records include the method’s matrix scope, calibration and controls near the concentration of interest, quantification limit, interference assessment, measurement uncertainty and handling history. Reviewers should also ask what the proposed threshold was designed to classify and under which specimen conditions.

These questions do not establish that a reported result is wrong. They define what is needed to assess its strength. Drug detection, a quantitative concentration, an inference of ingestion and an attribution of impairment or death remain separate conclusions. For a specific analytical comparison, see GHB measurement with different internal standards.

Primary sources

Pirani F, Busardò FP. The Difficult Interpretation of GHB Values in Postmortem Samples: What Strategies Should Be Followed? Journal of Analytical Toxicology. 44(9):e11–e12. Published online November 18, 2020. doi:10.1093/jat/bkaa130.

Andresen-Streichert H, Jensen P, Kietzerow J, et al. Endogenous gamma-hydroxybutyric acid (GHB) concentrations in post-mortem specimens and further recommendation for interpretative cut-offs. International Journal of Legal Medicine. 2015;129:57–68. doi:10.1007/s00414-014-1051-8.

A GHB cutoff developed for carefully collected blood from living volunteers cannot simply be transferred to autopsy blood. Shima and colleagues proposed 1.0 µg/mL only under specified antemortem collection and storage conditions. Their experiment did not validate that value as a postmortem exposure threshold.

Who supplied the blood?

The 2005 study measured whole blood from 24 healthy Asian volunteers: 14 men and 10 women, aged 25–55 years. Blood was collected aseptically into vacuum-stoppered polyethylene tubes, immediately cooled and stored at −20°C without added preservative. Processing occurred within three hours of collection, followed by prompt analysis. The paper did not specify a vascular collection site.

These were living-person specimens, not blood recovered after death or decomposition. The small, selected healthy-volunteer sample also did not represent all possible medical conditions or drug exposures.

Initial GHB concentrations ranged from 0.005 to 0.010 µg/mL, averaging 0.0069 ± 0.0020 µg/mL. The investigators found no obvious male–female difference. In equivalent units, 0.005–0.010 µg/mL equals 0.005–0.010 mg/L, or 5–10 ng/mL. Switching unit labels without converting the numbers could produce a thousandfold error.

The method was designed to measure very low concentrations

The laboratory used protein precipitation, trimethylsilyl derivatization and GC–MS. Selected-ion monitoring was used for concentrations at or below 0.03 µg/mL. Quantitation used standard addition and 2-hydroxycaproic acid as internal standard.

Detection limits were 0.03 µg/mL in full-scan mode and 0.003 µg/mL in selected-ion monitoring. The reported linear range was 0.003–3.0 µg/mL. Recovery at a 1.0 µg/mL spike was 63%. A nominal 0.10 µg/mL control measured 0.096 ± 0.015 µg/mL in five measurements; reported within-day and between-day precisions were 5.3% and 6.1%.

These analytical characteristics explain how the study measured trace endogenous GHB. They are not the diagnostic sensitivity or specificity of an exposure cutoff.

Storage experiments did not reproduce autopsy conditions

The study also examined additives and storage. Anticoagulant experiments used three preparations per condition, rather than the full 24-person cohort. Sodium citrate and heparin produced larger increases than EDTA or sodium oxalate under the tested conditions.

The long-term experiment used blood from three healthy volunteers, stored under different temperature and preservative conditions. After 16 months, reported in-vitro production was below 0.03 µg/mL at −20°C and below 0.4 µg/mL at 4°C. Room-temperature increases were larger. Sodium azide showed no remarkable benefit during refrigerated storage in that experiment.

The authors did not establish a universal preservative recipe for postmortem specimens. Aseptic blood collected during life and blood exposed to postmortem biochemical and microbial changes present different problems.

The proposed cutoff had explicit conditions

The proposed 1.0 µg/mL value was limited to blood collected aseptically during life, stored at 4°C or below, examined within two weeks and interpreted after excluding GHB aciduria, a metabolic disorder. It was not a fatal-concentration threshold or a measure of impairment.

For a death investigation containing both hospital and autopsy specimens, the specimen’s origin and handling must travel with its result. This study supplies no formula for translating a hospital concentration into an autopsy concentration, or the reverse.

For a separate postmortem method issue, see how internal standards affected reported GHB concentrations. Both specimen context and measurement procedure matter.

Primary source

Shima N, Miki A, Kamata T, Katagi M, Tsuchihashi H. Endogenous Level and in Vitro Production of GHB in Blood from Healthy Humans, and the Interpretation of GHB Levels Detected in Antemortem Blood Samples. Journal of Health Science. 2005;51(2):147–154. doi:10.1248/jhs.51.147.

No. A nonsignificant difference in average GHB concentrations does not mean that every stored specimen remained unchanged. In a ten-case frozen-storage comparison, average heart and peripheral blood results did not change significantly after two years at −20°C, but one heart-blood result more than doubled.

What was actually retested?

Andresen-Streichert and colleagues included a long-term storage assessment within their broader postmortem GHB investigation. Blood from ten autopsy cases was analyzed again 24 months after the first measurement: ten heart-blood specimens and ten peripheral venous-blood specimens. These were paired repeat measurements from ten cases, not twenty independent deaths.

The broader study used specimens analyzed on the day of collection or immediately stored at −20°C. Its principal autopsy series had death-to-autopsy intervals of one to eleven days. Those overall intervals should not be treated as a separately established range for the ten-case storage subgroup.

The comparison tested what happened between two laboratory measurements during frozen storage. It did not compare blood during life with blood at autopsy and did not measure the amount of GHB formed before collection.

The averages and the individual exception

Heart-blood GHB averaged 21.6 ± 16.1 mg/L initially and 20.4 ± 16.8 mg/L at repeat testing. The paired comparison was nonsignificant, p = 0.779. Peripheral blood averaged 17.5 ± 7.2 mg/L initially and 15.2 ± 6.4 mg/L after storage, also nonsignificant, p = 0.312.

The individual trajectories were not identical. Heart-blood GHB increased more than twofold in one case, while the other nine results decreased. Peripheral GHB increased in one case and decreased in nine. All ten peripheral results remained below the study’s proposed 30 mg/L interpretive cutoff at both measurements.

That last finding supports a limited observation: none of these peripheral specimens crossed that threshold. It does not establish the maximum possible storage change in other specimens or show that no case near a threshold could change classification.

What “no significant difference” does and does not show

The authors used paired t tests. A p value above 0.05 means the test did not find a statistically significant difference under its assumptions. It is not a calculated probability that every specimen was stable. The study did not set and demonstrate an equivalence margin for individual specimen changes.

With only ten cases, the data cannot precisely characterize uncommon increases or all combinations of starting concentration, preservation and handling. The authors themselves called for further stability work in urine, vitreous humor and cerebrospinal fluid. A blood-storage result should not be extended to those matrices without additional evidence.

How analytical performance enters the comparison

GHB was quantified by derivatization GC–MS with GHB-d6 internal standard. The method’s detection and quantification limits were 0.5 and 0.6 mg/L; the reported linear calibration range was 1–100 mg/L. Validation at the tested controls gave accuracy of at least 91% and imprecision of 9% or less.

Those validation findings help assess the measurement procedure. They do not prove that every difference on repeat analysis came from storage, nor do they erase the observed specimen-level exception. Analytical variation and specimen change remain separate issues to evaluate.

What to retain in a case review

Keep both concentrations, both analysis dates, specimen site and the documented storage history. An unchanged classification after storage is different from an unchanged numerical concentration. Neither establishes GHB intake, impairment or contribution to death.

For evidence under different storage conditions, see GHB increases in stored postmortem blood. Its refrigeration and preservation experiments should not be conflated with this two-year frozen comparison.

Primary source

Andresen-Streichert H, Jensen P, Kietzerow J, et al. Endogenous gamma-hydroxybutyric acid (GHB) concentrations in post-mortem specimens and further recommendation for interpretative cut-offs. International Journal of Legal Medicine. 2015;129:57–68. doi:10.1007/s00414-014-1051-8.

Cerebrospinal fluid can provide useful additional evidence in postmortem GHB testing, particularly when urine is unavailable. A five-matrix autopsy study found generally lower GHB concentrations in cerebrospinal fluid than in peripheral blood. It did not establish that cerebrospinal fluid alone can prove or exclude ingestion.

The study and its collection conditions

Andresen-Streichert and colleagues examined a main series of 64 autopsies collected between January 2009 and November 2012. A forensic pathologist considered GHB exposure excluded as the cause of death. This classification was not independent proof that no person had ever ingested GHB.

The death-to-autopsy interval ranged from one to eleven days, averaging 4.8 days. Samples were analyzed on the collection day or immediately frozen at −20°C; the initial storage interval extended to 21 months in some cases. Peripheral venous blood, heart blood, urine, vitreous humor and cerebrospinal fluid were collected when available. The report’s ratio table identifies the peripheral comparator as femoral vein blood.

The actual matrix counts differed: 61 peripheral blood specimens, 56 heart blood, 50 urine, 54 vitreous and 52 cerebrospinal fluid. An unavailable specimen is missing information, not a negative result.

How cerebrospinal fluid compared

Cerebrospinal fluid GHB ranged from below 0.6 to 24.0 mg/L, with a mean of 4.2 and median of 3.2 mg/L. Forty-eight of 52 specimens were below 10 mg/L. Peripheral blood ranged from below 0.6 to 28.7 mg/L, with a mean of 11.9 and median of 10.6 mg/L.

Among 47 available cerebrospinal-fluid/peripheral-blood pairs, ratios ranged from 0.03 to 1.17, with a median of 0.37. The paper reported no statistically significant difference among the five specimen types overall. Lower descriptive averages therefore did not establish a significant matrix difference or create a fixed conversion factor. The correlation with peripheral blood was only moderate, r = 0.411.

Vitreous humor was not uniformly lower than blood: its range extended to 39.0 mg/L, and three of 54 vitreous specimens exceeded 30 mg/L. These findings explain why the authors favored obtaining more than one companion matrix where possible, rather than assuming every alternative specimen behaves alike.

What the analytical procedure could measure

The investigators quantified GHB by extraction, derivatization and GC–MS with GHB-d6 as internal standard. The detection limit was 0.5 mg/L and the quantification limit 0.6 mg/L. Calibration was linear from 1 to 100 mg/L. Reported inter- and intra-day accuracy was at least 91%, and imprecision no greater than 9% at the tested quality-control concentrations.

Recovery for cerebrospinal fluid and vitreous was approximately 19%, compared with approximately 30% in urine and serum. Recovery is an extraction characteristic, not the proportion of cases the test correctly classifies. Values below quantification were assigned zero for the study’s statistical calculations; that convention did not prove absence of GHB.

A conditional cutoff, not a diagnostic verdict

The authors proposed 30 mg/L for cerebrospinal fluid, urine and peripheral blood under the studied same-day-analysis or immediate-freezing conditions. They could not calculate diagnostic sensitivity or specificity from this cohort. A value below the proposed threshold is therefore not proof of no intake, and a value above it is not automatically proof of a fatal dose.

Ten additional cases with putrefaction were assessed separately. Their concentrations were not significantly higher overall than those in the main series; this small comparison did not establish that advanced decomposition is harmless. One advanced-putrefaction case had peripheral blood GHB of 32.7 mg/L.

Collection feasibility, specimen identity, handling and independent case evidence remain essential. A quantified concentration in cerebrospinal fluid does not establish impairment or cause of death. Compare the separate study of brain GHB and decomposition, which concerns a different tissue and different units.

Primary source

Andresen-Streichert H, Jensen P, Kietzerow J, et al. Endogenous gamma-hydroxybutyric acid (GHB) concentrations in post-mortem specimens and further recommendation for interpretative cut-offs. International Journal of Legal Medicine. 2015;129:57–68. doi:10.1007/s00414-014-1051-8.

A urine GHB result above a proposed postmortem cutoff can support investigating exposure without establishing the GHB concentration in blood at death. Loos and colleagues described two cases with urine concentrations of 35 and 72 mg/L, while femoral blood was below 10 mg/L in both. Those paired findings cannot be reduced to one positive-or-negative answer about fatal intoxication.

What the two cases actually involved

The 2023 report described two men found dead after circumstances involving several drugs. Femoral blood and urine were collected at the scene during external examinations. Neither case underwent a forensic autopsy. The authors discussed them as fatal mixed intoxications, but the report is not a controlled study identifying the independent contribution of GHB.

In the first case, drug-taking circumstances and materials including GBL were reported. Urine GHB measured 35 mg/L and femoral blood was below 10 mg/L. Other substances were detected in the investigation. The estimated postmortem interval was approximately six hours; that estimate should not be treated as a precise death-to-collection timestamp.

In the second case, the history included MDMA and GHB use, subsequent illness and tramadol ingestion. Urine GHB measured 72 mg/L and femoral blood was again below 10 mg/L. The reported postmortem interval was approximately two hours. Multiple other substances were detected, and ethanol measured 1.6 g/L in blood and 2.3 g/L in urine. The different units for ethanol and GHB must remain explicit.

Screening and quantitative GHB testing were different steps

The investigation included on-site drug screening, immunochemical urine testing and blood drug screening by liquid chromatography with mass-spectrometric detection. Class-based immunochemical findings should not be upgraded to confirmed identification or quantitation of every individual drug.

GHB itself was measured using a chromatographic procedure described as GC–FID, involving conversion to gamma-butyrolactone in acid and a gamma-valerolactone internal standard. Thus, the numerical GHB findings were not simply positive immunoassay results. The article described the method as validated but did not provide numerical detection limits, quantification limits, precision or uncertainty for these case results. “Below 10 mg/L” should not be rewritten as zero.

Why urine and blood answer different questions

The authors used a proposed urine interpretive cutoff of 30 mg/L to flag possible exogenous exposure. Both urine results exceeded it. The paired blood results provided different information and did not demonstrate a high circulating GHB concentration in either specimen at collection.

This discordance does not establish that one matrix was analytically wrong. Nor does it permit a back-calculation from urine to blood at death. The report discusses rapid elimination during life and postmortem formation as interpretive problems, but it did not measure serial antemortem concentrations or experimentally partition those mechanisms in either case.

Storage recommendations in the discussion are also not equivalent to a complete documented handling history for each case specimen. Freezing after collection cannot retrospectively remove GHB that formed before collection.

What the cases support in practice

A review should retain both matrix-specific numbers, the collection circumstances, estimated interval, analytical method and evidence of exposure. It should distinguish the authors’ interpretation of the deaths from what the measured GHB concentrations alone establish. Two selected cases cannot validate a cutoff’s sensitivity, specificity or ability to diagnose fatal intoxication.

For a complementary collection-site problem, see cardiac blood GHB above 50 mg/L. Neither a high cardiac value nor a urine result should independently establish impairment or cause of death.

Primary source

Loos NHC, van den Hondel KE, Reijnders UJL, Franssen EJF. Complications in post-mortem GHB cut-off values in urine samples: A case report. Toxicology Reports. 2023;10:600–603. doi:10.1016/j.toxrep.2023.05.002.

“Methamphetamine-associated cardiovascular disease” covers more than one process. Acute changes in vessel tone, chronic plaque formation and injury to heart muscle require different evidence. A 2019 review helps separate those questions rather than treat every cardiac finding as one established drug mechanism.

What kind of source is this?

Kevil and colleagues reviewed clinical observations, pathology reports and experimental work. The paper did not recruit a single new cohort or conduct one experiment that tested every proposed mechanism. Its discussion spans human case reports, small human comparisons, animal models and cell systems.

These evidence types can complement one another, but they do not provide interchangeable estimates. A cellular response can support a mechanism hypothesis without measuring its frequency in patients, and an autopsy association does not by itself establish when a process began.

What is the difference between spasm and plaque?

Spasm concerns constriction of a coronary artery or smaller coronary vessels, potentially reducing blood supply. Atherosclerosis concerns structural plaque developing in vessel walls. They may coexist, but observing one does not demonstrate the other or identify the dominant mechanism of a particular event.

The review discusses reports of ischemia associated with vasospasm as well as pathology evidence of coronary artery disease. The distinction matters because neither the mere presence of plaque nor a proposed transient spasm can be inferred solely from detection of methamphetamine.

What did the small human vascular comparison measure?

The review summarizes a study of twenty methamphetamine users and twenty-one age-matched controls that found reduced nitroglycerine-mediated vasodilation in the user group. The authors interpreted it as evidence consistent with smooth-muscle dysfunction or reduced sensitivity to nitric-oxide-related signaling.

That comparison measured a vascular response, not the incidence of coronary spasm, myocardial infarction or death. It also does not establish that every person with a similar exposure history has the same response. The review’s summary is secondary evidence; it should not be expanded into unreported dose, route or concentration thresholds.

What do animal and cell experiments add?

The review describes greater plaque severity after chronic methamphetamine treatment in atherosclerosis-prone apolipoprotein E knockout mice. Such experiments can test exposure effects within a controlled model. The predisposed mouse strain is part of that model, not a representative sample of human susceptibility.

Cell and animal findings also involved oxidative stress, endothelial activation and inflammatory signaling. Experiments using human-derived cells remain laboratory experiments; they are not clinical outcome measurements merely because the cells originated from humans. Concentration, exposure duration and experimental conditions are necessary before translating a particular cellular result.

Did the review establish a single pathway?

No. The authors discussed several possible contributors, including vascular signaling, catecholamine effects, endothelial dysfunction and inflammation. They repeatedly identified gaps, including limited understanding of how methamphetamine changes vascular smooth-muscle behavior.

A plausible pathway is not proof that it operated in a particular person. Likewise, a case report of vasospasm unresponsive to vasodilator therapy demonstrates a reported clinical course, not a universal response or a comparative treatment rule. This historical review does not establish current clinical guidance.

How should this evidence be used in a death or injury review?

Identify the actual cardiovascular finding first: structural plaque, documented ischemia, rhythm disturbance, ventricular dysfunction or another endpoint. Then distinguish what was directly observed from what remains a proposed explanation. Relevant exposure timing, alternative causes and the clinical and pathological record remain essential.

The review supports investigating multiple cardiovascular processes associated with methamphetamine. It does not turn a positive drug result into proof of coronary spasm, date plaque formation or assign the cause of an individual cardiac event. Keeping these claims separate makes the scientific explanation more precise.

Source

Kevil CG et al. Methamphetamine Use and Cardiovascular Disease: in search of answers. Arteriosclerosis, Thrombosis, and Vascular Biology. 2019;39:1739–1746. doi:10.1161/ATVBAHA.119.312461. Historical narrative review spanning human observational, case-report, animal and cell evidence.